Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.EJCA.2003.09.022PMID 14728945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preclinical Perspectives on Platinum Resistance

  2012cited by this paper
• Reduced cardiotoxicity of doxorubicin given in the form ofN-(2-hydroxypropyl) methacrylamide conjugates: an experimental study in the rat

  2004cited by this paper
• The Biology of the Ets1 Proto-Oncogene

  2003cited by this paper
• Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.

  2003cited by this paper
• Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy.

  2003cited by this paper
• HPMA Copolymers Platinates Containing Dicarboxylato Ligands. Preparation, Characterisation and In Vitro and In Vivo Evaluation

  2002cited by this paper
• Vascular Morphogenesis and Remodeling in a Human Tumor Xenograft: Blood Vessel Formation and Growth After Ovariectomy and Tumor Implantation

  2001cited by this paper
• Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

  2001cited by this paper
• Water soluble polymers in tumor targeted delivery.

  2001cited by this paper
• Efficacy of the chemotherapeutic action of HPMA copolymer‐bound doxorubicin in a solid tumor model of ovarian carcinoma

  2000cited by this paper
• Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation.

  2000cited by this paper
• HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action.

  2000cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Polymer-bound camptothecin: initial biodistribution and antitumour activity studies.

  2000cited by this paper
• Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

  1999cited by this paper
• Comparison of the Anticancer Effect of Free and HPMA Copolymer-Bound Adriamycin in Human Ovarian Carcinoma Cells

  1999cited by this paper
• HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo.

  1999cited by this paper
• Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.

  1999cited by this paper
• Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.

  1998cited by this paper
• Prognostic significance of cathepsins B and L in primary human breast cancer.

  1998cited by this paper
• Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues

  1998cited by this paper
• Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.

  1994cited by this paper
• Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.

  1992cited by this paper
• Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro.

  1989cited by this paper
• Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model.

  1989cited by this paper
• Degradation of side-chains ofN-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases

  1982cited by this paper

• A nanoformulation of cisplatin with arabinoxylan having enhanced activity against hepatocellular carcinoma through upregulation of apoptotic and necroptotic pathways

  2024cites this paper
• Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC).

  2024cites this paper
• Platinum-based chemotherapy: trends in organic nanodelivery systems.

  2024cites this paper
• Stearyl polyoxyethylene-grafted heparin nanogel for oral delivery of Cisplatin: enhanced drug loading capacity and anticancer efficacy

  2024cites this paper
• Targeted nanomedicine in cisplatin-based cancer therapeutics.

  2022cites this paper
• Cisplatin-Loaded Tobacco Mosaic Virus for Ovarian Cancer Treatment.

  2022cites this paper
• Nanotechnology advances in ovarian cancer

  2021cites this paper
• Versatile Applications of Metallopolymers

  2021cites this paper
• Concise Encyclopedia of Biomedical Polymers and Polymeric Biomaterials Adhesives — Medical Devices and Preparative Medicine

  2019cites this paper
• Recent progress in polymer-based platinum drug delivery systems

  2018cites this paper
• Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications

  2018cites this paper
• Nanoformulation as a Tool for Improve the Pharmacological Profile of Platinum and Ruthenium Anticancer Drugs

  2017cites this paper
• Anticancer Agents: Polymeric Nanomedicines

  2017cites this paper
• Nanoparticle formulations of cisplatin for cancer therapy.

  2016cites this paper
• Polymer Drug Conjugates: Recent Advancements in Various Diseases.

  2016cites this paper
• Polymeric Prodrugs Containing Metal-Based Anticancer Drugs

  2015cites this paper
• Synthesis and properties of a new micellar polyphosphazene-platinum(II) conjugate drug.

  2014cites this paper
• Complex of cisplatin with biocompatible poly(ethylene glycol) with pendant carboxyl groups for the effective treatment of liver cancer

  2014cites this paper
• Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.

  2014cites this paper
• Clinical translational challenges in nanomedicine

  2014cites this paper
• Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment

  2014cites this paper
• Nanocarriers for delivery of platinum anticancer drugs.

  2013cites this paper
• Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity

  2012cites this paper
• Preclinical evaluation of a novel drug delivery system for cisplatin

  2012cites this paper
• Antiangiogenic gene therapy with soluble VEGF‐receptors ‐1, ‐2 and ‐3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma

  2012cites this paper
• Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy

  2012cites this paper
• Biological characterization of folate-decorated biodegradable polymer-platinum(II) complex micelles.

  2012cites this paper
• From metallodrugs to metallodendrimers for nanotherapy in oncology: a concise overview.

  2012cites this paper
• Water Soluble Polymers for Pharmaceutical Applications

  2011cites this paper
• New Trends and Future Developments of Platinum‐Based Antitumor Drugs

  2011cites this paper
• Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy

  2011cites this paper
• Electrostatic Interaction of Negatively Charged Core–Shell Nanoparticles with Antitumoral Cationic Platinum‐Based Complexes

  2011cites this paper
• Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.

  2010cites this paper
• Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy

  2010cites this paper
• Synthesis, characterization, and in vivo evaluation of poly(ethylene oxide-co-glycidol)-platinate conjugate.

  2010cites this paper
• HPMA copolymers for modulating cellular signaling and overcoming multidrug resistance.

  2010cites this paper
• Structural and chemical aspects of HPMA copolymers as drug carriers.

  2010cites this paper
• HPMA-Anticancer Drug Conjugates

  2010cites this paper
• Platinum drug distribution in cancer cells and tumors.

  2009cites this paper
• Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt.

  2009cites this paper
• Polymeric drug delivery of platinum-based anticancer agents.

  2009cites this paper
• The drug targeting and delivery approach applied to pt-antitumour complexes. A coordination point of view.

  2009cites this paper
• Pharmacokinetics and tissue distribution of PGG–paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts

  2009cites this paper
• Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane

  2009cites this paper
• ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic.

  2009cites this paper
• Synthetic Polymers as Drug-Delivery Vehicles in Medicine

  2008influential citation
• Novel designed polymer–acyclovir conjugates with linker-controlled drug release and hepatoma cell targeting

  2008cites this paper
• Synthesis and biological characterisation of HPMA copolymer-mannose conjugates designed for intracellular delivery of anti-leishmanial compounds to macrophages.

  2008cites this paper
• Development of chitosan-ellagic acid films as a local drug delivery system to induce apoptotic death of human melanoma cells.

  2008cites this paper
• Chemo-enzymatic synthesis and sustained release of optically active polymeric prodrugs of chlorphenesin

  2008cites this paper
• Anticancer Polymeric Nanomedicines

  2007cites this paper
• Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity.

  2007cites this paper
• Degradable Cisplatin-Releasing Core-Shell Nanogels from Zwitterionic Poly(β -Aminoester)-Graft-PEG for Cancer Chemotherapy

  2007cites this paper
• Acidic hydrolysis of N-Ethoxybenzylimidazoles (NEBIs): potential applications as pH-sensitive linkers for drug delivery.

  2007cites this paper
• Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.

  2006cites this paper
• Recent developments in the field of anticancer platinum complexes.

  2006cites this paper
• N-(2-Hydroxypropyl) methacrylamide Copolymer

  2005cites this paper
• Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers.

  2005cites this paper
• Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles.

  2005cites this paper
• Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.

  2005cites this paper
• Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity

  2005cites this paper
• Synthetic polymers as drugs and therapeutics

  2005cites this paper